Welcome to our dedicated page for Immuneering SEC filings (Ticker: IMRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Immuneering Corporation filings document the disclosure record of a late-stage clinical oncology company developing Deep Cyclic Inhibitors for cancer. Recent Form 8-K reports cover operating and financial results, R&D spending, capital resources, and clinical updates for atebimetinib (IMM-1-104), including its evaluation with modified gemcitabine/nab-paclitaxel in first-line pancreatic cancer.
Proxy materials describe annual meeting matters for holders of Class A common stock, including director elections, auditor ratification, board governance and voting procedures. The filing record also includes material-event disclosures addressing material agreements, capital-structure matters, shareholder votes, and regulatory and clinical disclosures for the company’s oncology development programs.
Immuneering filed a Form S-3 registering up to $300,000,000 of securities, including Class A common stock, preferred stock, debt securities, warrants and units, available from time to time under a shelf registration. The filing also includes an equity distribution agreement prospectus supplement that covers the potential sale of up to $100,000,000 of Class A common stock under an agreement with Piper Sandler & Co., and states that those shares are included in the $300,000,000 shelf amount.
The prospectus describes the company as a clinical-stage oncology developer focused on Deep Cyclic Inhibition (DCI) and names its lead candidate atebimetinib (IMM-1-104), an oral once-daily DCI targeting the MAPK pathway. The registrant is listed on the Nasdaq Global Market under the symbol IMRX, with a reported last sale price of $3.25 per share on August 12, 2025. The prospectus incorporates risk factors and forward-looking statements, and discloses governance provisions such as a classified board, exclusive Delaware forum clauses and indemnification of directors and officers.
Immuneering Corporation is a clinical-stage oncology company focused on Deep Cyclic Inhibition of the MAPK pathway with lead candidate atebimetinib (IMM-1-104) in a Phase 1/2a trial. Interim data from the mGnP combination arm at the 320 mg once-daily dose show a 6‑month overall survival of 94% and 6‑month progression-free survival of 72% in the 34‑patient intent-to-treat cohort; among 36 response-evaluable patients at 240/320 mg, the interim disease control rate was 81% and overall response rate was 39%. Safety at the 320 mg dose was described as generally well tolerated with Grade ≥3 events ≥10% limited to Anemia 18% and Neutropenia 15%, and no Grade 5 events reported.
On the financial side, cash and cash equivalents were $26.36 million at June 30, 2025, down from $36.14 million at year-end; the company reported a net loss of $29.48 million for the six months and used $23.53 million in operating cash during the period. The company raised $13.7 million net from an ATM equity program in the six months. Management disclosed substantial doubt about the company’s ability to continue as a going concern for one year without additional funding and plans to pursue further financing and strategic options.
Immuneering Corporation announced its financial results for the quarter ended June 30, 2025 and provided operational updates, and the company furnished the full press release as Exhibit 99.1 to this Current Report. The 8-K itself does not contain the detailed financial figures or operational text; those details are included in the attached press release.
The filing explicitly states that the information is furnished, not filed, meaning it is not subject to Section 18 liabilities of the Exchange Act and is not incorporated by reference into other filings except by specific reference. This document serves as a formal vehicle to make the quarter-end results and operational commentary publicly available, while the substantive metrics and narrative are contained in the exhibit.
Form 4 discloses that Benjamin J. Zeskind – President, CEO, Director and 10% owner of Immuneering Corp. (IMRX) – purchased additional Class A common shares on two consecutive days.
- 07/01/2025: 2,985 shares acquired at a weighted-average price of $3.3792.
- 07/02/2025: 7,015 shares acquired at a weighted-average price of $3.5342.
Following these open-market purchases (Transaction Code P), Zeskind now owns 2,305,837 shares directly and 894,927 shares indirectly through the Benjamin J. Zeskind 2020 Family Trust (sole trustee: Lisa Schwartz).
The filing signals incremental insider confidence, although the 10,000-share purchase represents less than 0.5% of Zeskind’s combined direct and indirect holdings. No derivative transactions were reported, and no sales occurred.
Immuneering Corp. (IMRX) Form 4 filing: On 24 June 2025 the company reported two open-market insider purchases by Chief Scientific Officer Brett Matthew Hall.
• 20 Jun 2025 – Hall bought 7,415 Class A common shares at a weighted-average price of $2.6999.
• 23 Jun 2025 – Hall bought 6,007 Class A common shares at a weighted-average price of $2.4299, with individual trades executed between $2.4101 and $2.4299 (per footnote 1). Both transactions were coded “P,” confirming they were purchases rather than option exercises.
No derivative securities were reported in Table II. Following the purchases Hall now directly owns 359,318 Class A shares, up from 345,896 beforehand—an increase of roughly 3.9 %. The filing does not mark the Rule 10b5-1 safe-harbor box and contains no amendments or dispositions.
Immuneering Corporation (IMRX) filed a Form 4 on 24-Jun-2025 disclosing a small insider purchase. Chief Business Officer Harold E. Brakewood acquired 1,900 shares of Class A common stock on 20-Jun-2025 at an average price of $2.5285 per share, for an estimated total cost of about $4,805. Following the transaction, Brakewood’s direct beneficial ownership rose from 3,900 to 5,800 shares.
The filing reports no derivative activity and contains no other transactions or amendments. Because the share count and dollar value are modest relative to Immuneering’s public float, the transaction is considered routine and unlikely to materially affect the company’s capital structure or near-term valuation. Nevertheless, insider purchases can signal management’s confidence in the company’s prospects, which some investors view positively.
Form 4 filing overview for Immuneering Corp (IMRX): Director Peter Feinberg reported an open-market purchase of 25,000 Class A common shares on 06/18/2025 at a weighted-average price of $2.5275. The transaction was executed through multiple trades between $2.07 and $2.96.
Post-transaction ownership: Feinberg now holds 136,766 shares directly. In addition, he retains indirect ownership as general partner of three entities: 392,242 shares via PF Associates L.P., 476,615 shares via PEF LLC, and 115,441 shares via S4K Investments LLC, bringing his total reported beneficial ownership to approximately 1.12 million IMRX shares.
Key takeaways for investors:
- The filing reflects a net increase in insider holdings; no dispositions were reported.
- The purchase price is near recent trading lows, signalling potential confidence by a board member in the company’s valuation.
- No 10b5-1 plan was checked, indicating the transaction was not pre-scheduled under Rule 10b5-1.